| Mental Retardation |
2010-021343-41: Variations of blood phenylalanine and tyrosine in children with phenylketonuria under sapropterin |
|
|
| Ongoing | 4 | 20 | Europe | Soluble tablet, Kuvan | University Medical Center Groningen, Merck KGaA | Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder by a mutation in the gene for the enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional. Left untreated, the disease will result in high concentrations of phenylalanine (Phe) in blood and tissues, likely resulting in severe mental retardation and behavioural problems. Treatment focusus on the restriction of dietary phenylalanine intake with supplementation of a synthetic phenylalaninefree amino acid mixture., Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder. Untreated, PKU can lead to mental retardation and behavioural problems., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2014-002002-20: A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate |
|
|
| Ongoing | 4 | 120 | Europe | Capsule, hard, Concerta | UMCG, ZonMw, Shire | attention-deficit/hyperactivity disorder, attention-deficit/hyperacitivity disorder (ADHD), Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2011-001088-28: Trial to study the use of injectable buprenorphine in patients who persist in using illicit heroin to find an acceptable dose that could help reduce the use of illicit heroin |
|
|
| Ongoing | 4 | 10 | Europe | Buprenorphine, Injection, Temgesic Injection 1ml | South London and Maudsley NHS Foundation Trust, King's College London, Action on Addiction & National Addiction Centre | Addiction to illicit heroin, Addiction to illicit heroin, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2016-001217-25: Emotion, Serotonin and Premenstrual Dysphoric Disorder (EmSeP) |
|
|
| Not yet recruiting | 4 | 50 | Europe | Cipralex, N06AB10, Tablet, Cipralex - Escitalopram (Lundbeck) | Uppsala University, Swedish Research Council | Premenstrual Dysphoric Disorder, Mood disorder with onset of mood and physical symptoms in the luteal phase of the menstrual cycle, a decline in symptom severity after onset of menstruation., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-004064-35: Liraglutide and the management of overweight and obesity in people with schizophrenia |
|
|
| Not yet recruiting | 4 | 60 | Europe | Saxenda, Placebo, Injection, Saxenda | Southern Health NHS Foundation Trust, Novo Nordisk limited | Schizophrenia, schizoaffective disorder or first episode psychosis, Severe mental illness, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-004706-18: Long acting naltrexone for opioid addiction: the importance of mental, physical and societal factors for sustained abstinence and recovery |
|
|
| Not yet recruiting | 4 | 150 | Europe | Vivitrol (Extended-release naltrexone hydrochloride for extended-release injectable suspension), N07BB04, Injection, Vivitrol | Akershus University Hospital, Norwegian Research Council, Akershus University Hospital, Haukeland University Hospital, Sørlandet Hospital Trust, Vestfold Hospital Trust, Oslo University Hospital Trust | Opioid addiction, Addiction to heroin and other opioids, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-002097-38: SAM study: an epigenetic therapy for depression after childhood trauma |
|
|
| Ongoing | 4 | 100 | Europe | S-Adenosylmethionine, Tablet | University Medical Centre Utrecht, ZonMw, Hersenstichting, University Medical Centre Utrecht | Bipolar depression, depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-004834-26: What is the influence on the amount of clozapine in a patient's blood whenclozapine is used once daily instead of twice daily? Wat is het effect op de hoeveelheid clozapine in het bloed als clozapine éénkeer per dag wordt gebruikt in plaats van twee keer per dag? |
|
|
| Not yet recruiting | 4 | 50 | Europe | clozapine | Albert Schweitzer hospital, Scientific committee of the Albert Schweitzer hospital | Schizophrenia Schizofrenie, Schizophrenia Schizofrenie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Not yet recruiting | 4 | 60 | Europe | DM-Aripiprazole, DM-Olanzapine, DM- Quetiapine, DM-Risperidone, Tablet, Aripiprazole, Olanzapine, Quetiapine, Risperidone | Otsuka Pharmaceutical, Otsuka Pharmaceutical | Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001023-13: PAX-D: Randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression |
|
|
| Ongoing | 4 | 204 | Europe | Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg, Tablet, Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg | University of Oxford / Clinical Trials and Research Governance, National Institute for Health Research (NIHR) | Treatment resistant depression, Clinical depression that has not responded to two antidepressant treatments, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2013-000970-31: Randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) for acute suicidal ideation and behaviour in patients with suicidal major depressive episode |
|
|
| Not yet recruiting | 4 | 254 | Europe | Capsule, Quilonum retard | Technische Universität Dresden, Bundesministerium für Bildung und Forschung, American Suicide Foundation | Diagnosis of a major depressive episode; inpatient at screening visit; suicidal ideation/behaviour present defined by a clinical rating of ≥ 8 on the Sheehan Suicidality Tracking Scale (S-STS) at screening and a rating of ≥20 on the Montgomery Asberg Depression Scale (MADRS) at both screening and baseline visits; both gender, age ≥18 years., patients who are severely depressive and have suicidal ideation or behaviour, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000102-28: Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine? Kan tillægsbehandling med glukagonlignende peptid-1 receptoragonisten semaglutid forebygge forværring af metaboliske forstyrrelser hos prediabetiske og diabtetiske skizofrene patienter, der er i behandling med olanzapin eller clozapin? |
|
|
| Not yet recruiting | 4 | 104 | Europe | Suspension for injection in pre-filled pen, Ozempic | Mental Healt Center Copenhagen, Novo Nordisk, Region Hovedstaden Psykiatri | Schizophrenia spectrum disorder F20-F29, Mental Health Psykisk sygdom, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-005726-29: An open label signal detection study to evaluate the effects of cariprazine on cognitive functioning in patients with schizophrenia in need of adjustment of oral antipsychotic treatment |
|
|
| Not yet recruiting | 4 | 20 | Europe | Capsule, hard, Reagila | Medical University Innsbruck, Gedeon Richter Plc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-005633-33: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine |
|
|
| Not yet recruiting | 4 | 100 | Europe | Rivastigmine, Transdermal patch, Rivastigmine | University Medical Center Groningen, Netherlands Organization for Scientific Research | A depressive disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001268-58: Investigation of effects of cariprazine in patients with mitochondrial schizophrenia A cariprazine hatásának vizsgálata mitochondriális dysfunkcióval asszociált schizophreniában |
|
|
| Not yet recruiting | 4 | 10 | Europe | Reagila, Capsule, Reagila | Semmelweis University, STIA-POC-2020, Semmelweis University, STIA-POC-2020, Gedeon Richter | Mitochondrial disease associated schizophrenia Mitochondrialis betegséghez társuló schizophrenia, schizophrenia associating with mitochondrial disease schizophrenia, amely mitochondrialis betegséghez társul, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2021-001817-35: Treatment of opioid dependency in patients with chronic pain: a comparative study between suboxone and methadone. Behandeling van opiaatafhankelijkheid bij pijn: een vergelijkende studie met suboxone en methadon. |
|
|
| Ongoing | 4 | 100 | Europe | Methadone, Sublingual tablet, Tablet, Suboxone, Methadone | Radboud University Medical Center, Dutch Research Council (NWO) | Opioid use disorder Stoornis in het opioïdgebruik, Dependence on opioids Afhankelijkheid aan opiaten, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-004404-18: Effect of antipsychotic therapy with aripiprazole long-acting on the brain structure of patients with a first episode of schizophrenia Impatto della terapia antipsicotica con aripiprazolo in formulazione a rilascio prolungato sulla struttura cerebrale dei pazienti al primo episodio di schizofrenia |
|
|
| Not yet recruiting | 4 | 15 | Europe | Abilify Maintena, [Aripiprazolo long-acting], Powder and solvent for prolonged-release suspension for injection, ABILIFY MAINTENA - 300 MG - POLVERE E SOLVENTE PER SOSPENSIONE A RILASCIO PROLUNGATO PER INIEZIONE - USO INTRAMUSCOLARE - FLACONCINO (VETRO) - POLVERE: 300 MG + SOLVENTE: 2 ML - 1 FLACONCINO POLVERE + 1 FLACONCINO SOLVENTE + 1 SIRINGA CON AGO + 1 SIR, ABILIFY MAINTENA - 400 MG - POLVERE E SOLVENTE PER SOSPENSIONE A RILASCIO PROLUNGATO PER INIEZIONE - USO INTRAMUSCOLARE - FLACONCINO (VETRO) - POLVERE: 400 MG + SOLVENTE: 2 ML - 1 FLACONCINO POLVERE + 1 FLACONCINO SOLVENTE + 1 SIRINGA CON AGO + 1 SIR | FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, Otsuka Pharmaceutical Italy s.r.l., Via Fabio Filzi 29, 20124 - Milano (MI) | Onset of schizophrenia Esordio di schizofrenia, Onset of symptoms of schizophrenia Prima presentazione di sintomatologia schizofrenica, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-005007-12: Study of Trazodone Once-a-Day for treatment of Depression in patients with breast cancer. |
|
|
| Not yet recruiting | 4 | 100 | Europe | Trittico XR 150 mg prolonged-release tablets, Trittico XR 300 mg prolonged -release tablets, Prolonged-release tablet, Trittico XR 150 mg prolonged-release tablets, Trittico XR 300 mg prolonged-release tablets | Angelini Pharma S.p.A., Angelini Pharma S.p.A. | Major Depressive Disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000696-39: Estrogen replacement therapy (ERT) for treatment of adolescent anorexia nervosa Not applicable |
|
|
| Not yet recruiting | 4 | 30 | Europe | Estradot, G03CA03, Transdermal patch, Estradot | Helse-Nord, Helse-Nord | Anorexia nervosa Anorexia nervosa, Anorexia Anoreksi, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001582-12: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode. Ensayo clínico abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de aripiprazol vs paliperidona / risperidona mediante datos multi-ómicos en pacientes con un primer episodio psicótico. |
|
|
| Ongoing | 4 | 244 | Europe | Injection, Abilify Maintena, Xeplion | Consorcio Centro de Investigacion Biomedica en Red (CIBER), Instituto de Salud Carlos III | First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-003237-19: The difference in the mechanism of action between two brands of dexamfetamine in adults with ADHD. Het verschil in de werkingsmechanisme tussen twee merken dexamfetamine bij volwassenen met ADHD. |
|
|
| Ongoing | 4 | 26 | Europe | Dexamfetamine, N06BA02, Tablet, Tentin | Amsterdam UMC, Amsterdam UMC, ADHDcentraal | Attention Deficit Hyperactivity Disorder (ADHD) Aandachtstekort Hyperactiviteitstoornis (ADHD), Attention Deficit Hyperactivity Disorder (ADHD) Aandachtstekort Hyperactiviteitstoornis (ADHD), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Not yet recruiting | 4 | 20 | Europe | GLIATILIN, [n.a.], Capsule, soft, GLIATILIN - 10 CAPSULE GELATINA MOLLE 600 MG | Azienda Socio Sanitaria Territoriale di Lodi, ITALFARMACO S.p.A. | Under threshold depression of the elderly. Depressione sottosoglia dell’anziano., n.a. n.a., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
EpiCom, NCT05864846: A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex |
|
|
| Recruiting | 4 | 75 | Europe, US | Cannabidiol Oral Solution [Epidiolex], Epidiolex | Jazz Pharmaceuticals | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | 01/26 | 01/26 | | |
TD-AIDD, NCT06107829: Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities |
|
|
| Not yet recruiting | 4 | 25 | US | Valbenazine Oral Capsule, Ingrezza | Stephen Ruedrich, Neurocrine Biosciences | Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities | 08/26 | 08/26 | | |
2009-014469-19: Multicentre randomised double-blind, placebo-controlled 2x2 factorial trial investigating the effects of adding mirtazapine and folic acid to existing therapy for people with schizophrenia. Trial clinico randomizzato in doppio cieco, multicentrico, con disegno fattoriale (2x2) per valutare l'efficacia dell'aggiunta di mirtazapina e acido folico alla terapia gia' in atto, in pazienti con schizofrenia |
|
|
| Ongoing | 3/4 | 334 | Europe | Mirtazapine, Folic acid, Tablet, Mirtazapin AL 30mg film tablets, TillVal Folsyra | University of Oxford, , Oxford University, UNIVERSITY OF OXFORD, Stanley Medical Research Institute, Meda AB, , University of Oxford | Schizophrenia, Schizophrenia Schizofrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-001878-29: Impact of a working method on traumatic memory under PROPRanolol in ADOlescents with post-traumatic stress syndrome (PROPRADO) Impact d’une méthode de travail sur la mémoire traumatique sous PROPRanolol chez des ADOlescents atteints du syndrome de stress post-traumatique (PROPRADO) |
|
|
| Not yet recruiting | 3 | 74 | Europe | chlorhydrate de propranolol, cellulose microcristalline, propranolol, placebo, Capsule | Rennes University Hospital, Hospital clinical research programme | post-traumatic stress disorder trouble du stress post-traumatique, PTSD TPST, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004006-26: Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia |
|
|
| Ongoing | 3 | 330 | Europe | cariprazine, RGH-188, Capsule, hard | Allergan Ltd, Allergan Ltd. | Adolescent Patients (13 to 17 years of age) with Schizophrenia, Adolescent Patients (13 to 17 years of age) with Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2015-002181-23: Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depressive Disorder. |
|
|
| Ongoing | 3 | 484 | Europe, RoW | Agomelatine, Fluoxetine, S20098, Film-coated tablet, Oral solution, Valdoxan, Fluoxetine | Institut de Recherche International Servier, ADIR | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-000061-23: A 12-Week Extension Study looking at the effects of Lurasidone (SM-13496) in Subjects with Schizophrenia |
|
|
| Ongoing | 3 | 283 | Europe | Lurasidone, SM-13496, Film-coated tablet, Latuda | Sunovion Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-003437-18: A phase 3 study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Schizophrenia |
|
|
| Ongoing | 3 | 308 | Europe | Pimavanserin, ACP-103, Tablet | ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc. | Schizophrenia, Chronic, debilitating mental illness characterized by disturbances in thinking, emotional reaction, and behavior, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-003074-14: A study to evaluate Samyr effectiveness and safety profile. The study is done by comparing that Samyr injection is better than placebo injection in subjects with depression which are treated regularly with antidepressant tablet treatment. Uno studio per valutare l'efficacia e il profilo di sicurezza di Samyr. Lo studio viene effettuato confrontando che l'iniezione di Samyr ¿ migliore dell'iniezione di placebo in soggetti con depressione trattati regolarmente con il trattamento con compresse antidepressive. |
|
|
| Ongoing | 3 | 468 | Europe | SAMYR, SAMYR, Powder and solvent for solution for injection, SAMYR - 400 MG/5 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 5 FLACONCINI POLVERE + 5 FIALE SOLVENTE 5 ML | MYLAN INC., Mylan Inc. | Major Depression Disorders Disturbo Depressivo Maggiore, Major Depression Depressione maggiore, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 3 | 250 | RoW | LY03004, RISPERDAL® CONSTA®, TEST, REFERENCE, Powder and solvent for prolonged-release suspension for injection, EU Risperdal® Consta® | Nanjing Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., Ltd., Luye Pharma Group, Ltd. | schizophrenia, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004460-63: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Sublocade, Buprenorphine, METHADONE, Buprenorphine-Naloxone, Espranor Oral lyophilisate, RBP-6000, Solution for infusion in pre-filled syringe, Sublingual tablet, Oral liquid, Oral lyophilisate, SUBOXONE, Espranor | South London and Maudsley NHS Foundation Trust, King's College London, INDIVIOR UK | Opiod addiction, Opiod Addiction, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002640-25: A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 546 | Europe | Sage-217, Capsule | Sage Therapeutics, Inc., Sage Therapeutics, Inc. | MAJOR DEPRESSIVE DISORDER, MAJOR DEPRESSIVE DISORDER, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003251-37: A study to evaluate the safety of Pimavanserin therapy in subject with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 280 | Europe | Pimavanserin, ACP-103, Film-coated tablet | ACADIA Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002749-12: Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression |
|
|
| Not yet recruiting | 3 | 514 | Europe | ITI-007, Capsule | Intra-Cellular Therapies, Inc. (ITI), Intra-Cellular Therapies, Inc. (ITI) | Major depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression), Bipolar Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-002787-32: Antidepressant for the prevention of DEPression following first episode Psychosis trial |
|
|
| Not yet recruiting | 3 | 508 | Europe | Sertraline, Film-coated tablet | University of Birmingham, National Institute for Health Research | Patients with First Episode Psychosis., Patients who are experience symptoms of psychosis for the first time., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-001424-34: A study to Evaluate SAGE-217 for the Treatment of Adults with Post-Partum Depression |
|
|
| Not yet recruiting | 3 | 192 | Europe | SAGE-217, Capsule, hard | Sage Therapeutics, Inc., Sage Therapeutics, Inc. | POSTPARTUM DEPRESSION, POSTPARTUM DEPRESSION, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003252-20: A study of the safety of pimavanserin in adult subjects with major depressive disorder |
|
|
| Not yet recruiting | 3 | 420 | Europe | Pimavanserin, ACP-103, Film-coated tablet | ACADIA Pharmaceuticals Inc, Acadia Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, Acadia Pharmaceuticals Inc | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003164-31: The purpose of this study is to look into the safety and efficacy ofcariprazine as an add-on medication in the treatment of major depressivedisorder. |
|
|
| Not yet recruiting | 3 | 750 | RoW, Europe | Cariprazine, Capsule | Allergan Ltd., Allergan Sales LLC | Major Depressive Disorder, Clinical Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001192-17: A Study to Assess the Efficacy and Safety of Lumateperone as Add on Therapy in the Treatment of Patients with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 470 | RoW, Europe | Lumateperone, ITI-007, Capsule | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-002068-30: Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia |
|
|
| Not yet recruiting | 3 | 800 | Europe | Lumateperone, ITI-007, Capsule, Caplyta | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001172-41: A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 760 | RoW, Europe | Lumateperone, ITI-007, Capsule, CAPLYTA | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001212-29: A Study to Assess the Efficacy and Safety of Lumateperone as Add on Therapy in the Treatment of Patients with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 470 | Europe, RoW | Lumateperone, ITI-007, Capsule | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004532-30: A 24 month Open-Label, international study of paliperidone 6 month formulation in patients with who have completed study R092670PSY3015 Schizophrenia is a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs). |
|
|
| Not yet recruiting | 3 | 180 | Europe | 1092mg paliperidone palmitate extended release suspension for injection (eq. 700 mg paliperidone), 1560 mg paliperidone palmitate extended release suspension for injection (eq. 1000 mg paliperidone), R092670, Prolonged-release suspension for injection in pre-filled syringe | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC, Janssen-Cilag SpA, Janssen-Cilag International NV | Schizophrenia, Schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-004193-64: A Study to assess the effectivenss of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia. |
|
|
| Not yet recruiting | 3 | 402 | Europe | Brilaroxazine, RP5063, Tablet | Reviva Pharmaceuticals Holdings Inc., Reviva Pharmaceuticals Holdings Inc. | Acute Exacerbation of Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003714-39: Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia |
|
|
| Not yet recruiting | 3 | 400 | Europe | Valbenazine, NBI-98854, Capsule | Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2021-003850-21: Treating depression with anti-inflammatory drugs Behandeling van depressie met ontstekingsremmers |
|
|
| Ongoing | 3 | 140 | Europe | Celecoxib, Capsule, hard, Celecoxib | Amsterdam UMC, location VUmc, Amsterdam UMC, location VUmc, Hersenstichting | Immuno metabolic Depression Immuno metabole depressie, Depression with imflammation and energy-related symptoms Depressie met onstekingen en energie-gerelateerde symptomen, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001515-10: A Phase 3 study to assess the safety of KarXT and how it helps in reoccurrence prevention in people with psychosis associated with Alzheimer’s Disease Dementia as compared to placebo Un estudio de fase 3 para evaluar la seguridad de KarXT y cómo ayuda aprevenir la recurrencia en personas con psicosis asociada con la demenciapor enfermedad de Alzheimer en comparación con un placebo |
|
|
| Not yet recruiting | 3 | 380 | Europe, RoW | KarXT, [--], [n/a], Capsule, hard | Karuna Therapeutics, Karuna Therapeutics, Inc., Karuna Therapeutics, Karuna Therapeutics, Inc. | Psychosis Associated with Alzheimer’s Disease Dementia Psicosis asociada con la demencia de la enfermedad de Alzheimer, Delusions or hallucinations associated with mild to severe Alzheimer’s disease memory loss Delirios o alucinaciones asociados con la pérdida de memoria leve agrave de la enfermedad de Alzheimer, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001666-35: A rollover study for subjects that complete Kar-012, to assess Long-term Safety and Tolerability of KarXT in combination with specified atypical antipsychotics in Subjects with Inadequately Controlled Symptoms of Schizophrenia |
|
|
| Not yet recruiting | 3 | 280 | Europe | KarXT, Capsule, hard | Karuna Therapeutics, Inc., Karuna Therapeutics, Inc. | Schizophrenia, Brain disorder that causes altered state that affects a person's ability to think, feel, and behave clearly., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001665-12: A Phase 3 study to assess the safety and effectiveness of KarXT in combination with specific approved atypical antipsychotic medications to reduce the signs and symptoms of Schizophrenia in adult subjects. |
|
|
| Not yet recruiting | 3 | 400 | Europe | KarXT, Capsule, hard | Karuna Therapeutics, Inc., Karuna Therapeutics, Inc. | Schizophrenia, brain disorder that causes altered state of affect a person's ability to think, feel, and behave clearly., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000430-42: a study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. |
|
|
| Ongoing | 3 | 840 | Europe, RoW | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD) Major depressziós zavar (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000461-41: A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant. |
|
|
| Not yet recruiting | 3 | 538 | RoW, Europe | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-003073-33: A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antidepressant treatment in patients with major depressive disorder (MDD) Uno studio di ricerca per confrontare l'abilità antidepressiva e la sicurezza delle compresse di Samyr® rispetto alle compresse di placebo in aggiunta al trattamento con antidepressivi aggiuntivo nei pazienti con disturbo di depressione maggiore (MDD) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Samyr, [NA], Gastro-resistant tablet, SAMYR - 400 MG COMPRESSE GASTRORESISTENTI20 COMPRESSE | Mylan Inc., Mylan Inc. | Major Depression Disorder Disturbo Depressivo Maggiore, Major Depression Depressione maggiore, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001865-11: A Study to Test if TV-44749 is Effective in Relieving Schizophrenia |
|
|
| Not yet recruiting | 3 | 640 | Europe | Olanzapine, TV44749, Powder and solvent for prolonged-release suspension for injection | Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It is a severely debilitating psychotic disorder characterized by positive symptoms (eg, delusions, hallucinations, and grossly disorganized behavior) and negative symptoms (eg, affective flattening, alogia, and avolition)., Schizophrenia is a mental disorder that may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning and can be disabling, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000439-22: A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant. |
|
|
| Ongoing | 3 | 538 | Europe, RoW | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000688-22: A phase III study evaluating the efficacy and safety of Silexan in patients with mild to moderate depression Eine Phase 3 Studie zum Nachweis der Wirksamkeit und Sicherheit von Silexan bei Patienten mit einer leichten bis mittelschweren Depression |
|
|
| Not yet recruiting | 3 | 498 | Europe | Silexan, sertralin-biomo 50 mg Filmtabletten, WS® 1265, Capsule, soft, Tablet, Lasea®, Sertralin-biomo 50 mg Filmtabletten | Dr. Willmar Schwabe GmbH & Co. KG, Dr. Willmar Schwabe GmbH & Co. KG | Major Depressive Disorder Akute Episode einer depressiven Erkrankung, Depression Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000405-83: A clinical study to evaluate iloperidone in the treatment of patients with acute manic episodes associated with Bipolar I Disorder Badanie kliniczne oceniające stosowanie iloperidonu w leczeniu pacjentów z ostrymi epizodami manii związanymi z chorobą dwubiegunową typu I |
|
|
| Not yet recruiting | 3 | 400 | Europe, RoW | Iloperidone, VYV-683, Capsule, Tablet | Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals Inc. | Acute manic episodes associated with Bipolar I Disorder Ostre epizody manii związane z chorobą dwubiegunową typu I, Bipolar I Disorder Choroba dwubiegunowa typu I, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Recruiting | 3 | 800 | Europe, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 06/24 | 05/25 | | |
2018-004899-35: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148 |
|
|
| Not yet recruiting | 3 | 95 | US | Rexulti, Tablet, Rexulti | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Irritability Associated With Autism Spectrum Disorder, AutismAutism Spectrum DisorderASDIrritability, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-000723-40: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder ( Anchor ) |
|
|
| Not yet recruiting | 3 | 130 | US | Rexulti, Tablet, Rexulti | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Irritability Associated With Autism Spectrum Disorder (ASD), AutismIrritabilityAutism Spectrum DisorderASD, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
2017-001169-26: Evaluation of NaBen® (sodium benzoate) in treatment of schizophrenia in adults |
|
|
| Not yet recruiting | 2/3 | 348 | Europe | NaBen®(F.C.T.II), NaBen®(F.C.T.II), Film-coated tablet | SyneuRx International (Taiwan) Corp, SyneuRx International (Taiwan) Corp. | Treatment for Schizophrenia in Adults, Treatment for Schizophrenia in Adults, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001170-42: Two-part Clinical Study to Evaluate the Safety and Efficacy of NaBen® in Adults with Refractory Schizophrenia |
|
|
| Not yet recruiting | 2/3 | 287 | Europe, RoW | NaBen®(F.C.T.II), NaBen®(F.C.T.II), Film-coated tablet | SyneuRx International (Taiwan) Corp, SyneuRx International (Taiwan) Corp | Treatment for Refractory Schizophrenia in Adults, Treatment for treatment-resistant Schizophrenia in Adults, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-006062-36: A Phase II/III, randomized, 4-week, placebo-controlled study, designed to determine the safety, tolerability, and efficacy of evenamide (NW-3509) in patients with chronic schizophrenia. |
|
|
| Ongoing | 2/3 | 196 | Europe, RoW | Evenamide, NW3509, Capsule, hard | Newron Pharmaceuticals S.p.A., NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A, Newron Pharmaceuticals S.p.A., Newron Pharmaceuticals S.p.A | Chronic schizophrenia, Chronic schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-002093-34: Phase II / III, open-label, extension study designed to determine the long-term safety, tolerability and efficacy of evenamide (NW-3509) in patients with psychiatric disorders who participated in previous trials with evenamide. Studio di fase II/III, di estensione, in aperto, progettato per determinare la sicurezza a lungo termine, la tollerabilità e l'efficacia di evenamide (NW-3509) in pazienti con disturbi psichiatrici che hanno partecipato a precedenti studi con evenamide. |
|
|
| Not yet recruiting | 2/3 | 500 | Europe | Evenamide, [NW3509], Capsule, hard | NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A | Patients with psychiatric disorders who participated in a previous trial with evenamide. Pazienti con disturbi psichiatrici che hanno partecipato a una precedente sperimentazione con evenamide., Patients with psychiatric disorders who participated in a previous trial with evenamide. Pazienti con disturbi psichiatrici che hanno partecipato a una precedente sperimentazione con evenamide., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001352-33: A clinical trial to assess the efficacy, safety, and tolerability of AVP-786 versus placebo for the treatment of negative symptoms of schizophrenia |
|
|
| Not yet recruiting | 2/3 | 370 | Europe | Deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q], AVP-786, Capsule, hard | Otsuka Pharmaceutical Development & Commercialization, Inc., Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc, Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Negative symptoms of schizophrenia, Negative symptoms of schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2014-000647-32: A medical treatment trial investigating whether degarelix decreases the risk of persons with pedophilic disorder from committing sexual child molestation |
|
|
| Ongoing | 2 | 60 | Europe | Powder and solution for solution for injection, FIRMAGON | Karolinska University Hospital, Karolinska University Hospital | Pedophilia acccording to DSM-5 (F65.4), Men suffering from pedophilia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2014-001541-24: Neuroenhancement of Interpersonal Psychotherapy in Major Depression Augmentation von Interpersoneller Psychotherapie durch D-Cycloserin |
|
|
| Ongoing | 2 | 28 | Europe | Cycloserin-Kapseln, Capsule, hard, Cycloserine | University Medical Center Freiburg, University Medical Center Freiburg | Major Depression (ICD-10; F32.2/F33.2) Depressive Störung (ICD-10; F32.2/F33.2), Disorder in which the fundamental disturbances are a change in affect or mood to depression and a usually accompanied change in the overall level of activity. Störung deren Hauptsymptome eine Veränderung der Stimmung oder der Affektivität zur Depression hin und eine Veränderung des allgemeinen Aktivitätsniveaus sind., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Not yet recruiting | 2 | 172 | Europe | bumetanide, bumetanide, Tablet, Bumetanide | UMC Utrecht, Dutch Brain Foundation | Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Epilepsy, Autism, ADHD, Epilepsy, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-001567-37: Efficacy of dexmedetomidine for conscious sedation during dental treatement of uncooperative patients with intellectual disability and fear of dentists. |
|
|
| Ongoing | 2 | 30 | Europe | Solution for injection, Dexdor | University Medical Center Groningen, University medical Center Gronignen | dentophobia intellectual disability, Fear of dentist Intellectual disability, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001739-38: A study to evaluate the safety and tolerability of TAK-831 in patients with schizophrenia. |
|
|
| Not yet recruiting | 2 | 32 | Europe | TAK-831, Tablet | Takeda Development Centre Europe Ltd., Takeda Development Centre Europe Ltd. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-000645-48: Cystadane in the treatment of AGU Cystadane AGU-taudin hoidossa |
|
|
| Ongoing | 2 | 15 | Europe | Oral powder, Cystadane anhydrous | Minna Laine, Prof. Ritva Tikkanen, Orphan Europe SARL | Aspartylglucosaminuria Aspartyyliglukosaminuria, Aspartylglucosaminuria (AGU) is a progressive disease that results in severe mental retardation of the patients. The main symptom of the disease is the progressive loss of mental capabilities. Aspartyyliglukosaminuria (AGU) on vaikeaa kehitysvammaisuutta aiheuttava, etenevä lastenneurologinen tauti. Taudin pääoire on henkisen kehityksen taantuminen., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
2016-004973-42: This study tests whether BI 409306 prevents patients with a specific type of mental illness (attenuated psychosis syndrome) from becoming worse. This study looks at how well patients tolerate the medicine and how safe and effective it is over 1 year. |
|
|
| Not yet recruiting | 2 | 300 | Europe | BI 409306, BI 409306, Film-coated tablet | Boehringer Ingelheim Limited, Boehringer Ingelheim Limited | attenuated psychosis syndrome, attenuated psychosis syndrome, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-002232-16: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression |
|
|
| Not yet recruiting | 2 | 90 | Europe | TAK-653, TAK-653, Tablet | Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd | Treatment Resistant Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-004710-95: Extended-release injectable suspension naltrexone (XR-NTX) as an adjunct pharmacotherapy for prevention of drug use in patients with substance use disorder in treatment for ADHD |
|
|
| Not yet recruiting | 2 | 128 | Europe | Naltrexone, Injection, vivitrol | Beroendecentrum Stockholm, Beroendecentrum Stockholm, Alkermes, Swedish research council, Swedish research council for health, working life and welfare | Amphetamine dependence and ADHD (Attention-Deficit/Hyperactivity Disorder), Patients who fulfil DSMIV/5 criteria for amphetamine dependence and ADHD (Attention-Deficit/Hyperactivity Disorder), respectively, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-000445-39: A study comparing the safety and clinical effects of different formulations of a new vaccine, ACI-24 with placebo in patients with mild Alzheimer's disease |
|
|
| Ongoing | 2 | 45 | Europe | ACI-24, ACI-24, Suspension for injection | AC Immune SA, AC Immune SA | Alzheimer's Disease, Alzheimer's Disease, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-001212-30: A trial to study effects of a single dose Citalopram on emotion processing in patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals |
|
|
| Ongoing | 2 | 30 | Europe | Film-coated tablet, Citalopram | Central Institute of Mental Health, represented by commercial and administrative Director, Boehringer Ingelheim Pharma GmbH & Co KG | Borderline Personality Disorder, Borderline Personality Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2015-004745-70: Efficacy of ketamine nose-spray on acute suicidal thoughts and behaviour Effectiviteit van ketamine-neusspray op acute suïcidale gedachten en gedrag |
|
|
| Ongoing | 2 | 128 | Europe | ketalar, Nasal spray, solution in single-dose container, Ketalar | Academic Medical Center (AMC), Academic Medical Center | Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours. Acute suïcidaliteit, gedefinieerd als een snelle toename in suïcidale gedachten of gedrag vanaf de 'baseline' van patiënt., Acute suicidality, thoughts about the wish to kill oneself, or behaviour with either the aim to die or a significant likelyhood that one could die because of this behaviour. Acute suïcidaliteit, gedachten over de wens zichzelf van het leven te willen beroven, of gedrag met het doel te sterven of met een grote waarschijnlijkheid dat men als gevolg van het gedrag sterft, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-001166-42: Clinical research study to determine how "trazodone" can influence the sleep and how it works in the body after one or repeated doses taken by mouth, in children suffering from insomnia and with autism, intellectual disability or attention deficit hyperactivity disorder (ADHD) Estudio de investigación clínica para evaluar cómo puede influir la trazodona sobre el sueño, así como su funcionamiento en el cuerpo tras una o varias dosis tomadas por boca, en niños que sufran insomnio y autismo, discapacidad intelectual o trastorno por déficit de atención con hiperactividad (TDAH) |
|
|
| Ongoing | 2 | 36 | Europe | trazodone hydrochloride, 152PO17433, Oral drops, solution | Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A (Angelini S.p.A.), AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A., Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A (Angelini S.p.A.), AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. | Insomnia in children and adolescents with autism, intellectual disability or ADHD Insomnio en niños y adolescentes, con autismo, discapacidad intelectual o TDAH, Insomnia in children and adolescents with autism, intellectual disability or ADHD Insomnio en niños y adolescentes, con autismo, discapacidad intelectual o TDAH, Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-001884-21: Antidepressant trial of a novel P2X7 receptor blocker JNJ-54175446. |
|
|
| Not yet recruiting | 2 | 142 | Europe | JNJ-54175446, JNJ-54175446, Capsule, hard | Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge, Wellcome Trust, Janssen Pharmaceutica NV | Major depressive disorder with an incomplete response to monoaminergic antidepressants and with biomarker profile indicative of inflammation, People with: - major depressive disorder whose condition has not improved with the current antidepressant medications.- increased levels of inflammation., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-000014-38: A Phase IIa Study to Determine the Safety, Tolerability and Efficacy of a daily oral dose of THX-110 in Adult Patients with Tourette Syndrome (TS) |
|
|
| Not yet recruiting | 2 | 60 | Europe | THX-110 [Dronabinol], THX-110 [PEA (Palmitoylethanolamide)], Capsule, soft, Tablet, Dronabinol Capsules, USP | Therapix Biosciences Ltd., Therapix Biosciences Ltd. | Tourette Syndrome, Neuropsychiatric disorder characterized by multiple motor or vocal tics., Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-001683-29: A study to explore the efficacy JNJ-61393215 in the treatment of depression |
|
|
| Not yet recruiting | 2 | 218 | Europe | JNJ-61393215, 45-mg, Capsule, hard | Janssen-Cilag International NV, Janssen Research and Development, LLC | Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious Distress with Suboptimal Response to Standard Antidepressants, Major depression with anxiety, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001696-36: Study of efficacy of low-dose interleukin-2 in alteration of the immune system associated with depression Studio di efficacia dell’interleuchina-2 a basso dosaggio nelle alterazioni del sistema immunitario associate alla depressione |
|
|
| Not yet recruiting | 2 | 36 | Europe | Aldesleuchina, [Aldesleuchina], Powder for solution for injection | OSPEDALE SAN RAFFAELE, Unione Europea H2020 –SCI 2016-2017 | Depressive episode in course of mood disorder Episodio depressivo in corso di disturbo dell’umore, Depressive episode in course of mood disorder Episodio depressivo in corso di disturbo dell’umore, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001084-20: An experimental trial to investigate a new medicine (drug), TAK-041, in patients with schizophrenia |
|
|
| Not yet recruiting | 2 | 32 | Europe | TAK-041, Powder for oral suspension | Takeda Development Centre Europe Ltd., Takeda Development Centre Europe Ltd. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002106-52: CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease |
|
|
| Not yet recruiting | 2 | 40 | Europe | Cannabidiol, Capsule, hard | King's College London, South London and Maudsley NHS Foundation Trust, King's Health Partner's R&D Challenge Funds, Psychiatric Research Trust, Rosetrees' Trust | Alzheimer's disease patients with BPSD, Alzheimer's disease patients with behavioural and psychological symptoms e.g. anxiety, agitation, hallucinations and delusions, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2019-000695-41: A clinical study to explore the efficacy of JNJ-67953964 in the treatment of depression |
|
|
| Not yet recruiting | 2 | 180 | Europe | JNJ-67953964-AAA, Capsule | Janssen-Cilag International NV, Janssen Research and Development LLC | Major Depressive Disorder, depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002708-15: Flexible-dose Long-term Extension Study of Lu AF11167 in Patients WithSchizophrenia With Prominent Negative Symptoms |
|
|
| Not yet recruiting | 2 | 240 | Europe, RoW | Lu AF11167 modified-release tablet, Modified-release tablet | H. Lundbeck A/S, H. Lundbeck A/S | schizophrenia with persistent prominent negative symptoms, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003573-97: A Trial of Psilocybin in Clinical Depression Resistant to Standard Treatments |
|
|
| Not yet recruiting | 2 | 60 | Europe | Psilocybin, Capsule | King's College London, South London & Maudsley NHS Foundation Trust, National Institute for Health Research Clinician Scientist Fellowship Programme (CS-2017-17-007) | Major depressive disorder, Clinical depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000094-24: A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia |
|
|
| Ongoing | 2 | 576 | Europe, RoW | Risperidone, MK-8189, Tablet, Capsule, Risperdal (Risperdione) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001621-27: A study on ketamine as a treatment for depression and demoralization in patients with advanced cancer Een studie naar het effect van ketamine als behandeling voor depressie en demoralisatie bij patiënten met gevorderde kanker |
|
|
| Not yet recruiting | 2 | 10 | Europe | Solution for injection, Ketanest-S | University Medical Center Groningen, University Medical Center Groningen | Major depressive disorder Depressie, Depression Depressie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000437-41: A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients with treatment-resistant schizophrenia (TRS). Studio multicentrico pilota, in aperto, randomizzato, per valutare sicurezza, tollerabilità ed efficacia preliminare in tre gruppi paralleli con tre dosi fisse di Evenamide somministrate come terapia aggiuntiva a pazienti affetti da schizofrenia resistente al trattamento (TRS). |
|
|
| Not yet recruiting | 2 | 150 | Europe | Evenamide, [NW-3509], Capsule, hard | NEWRON PHARMACEUTICALS SPA | Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000439-32: An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication. Studio di estensione in aperto, multicentrico per valutare sicurezza, tollerabilità ed efficacia preliminare a lungo termine di evenamide come terapia aggiuntiva in pazienti affetti da schizofrenia resistente al trattamento (TRS) che non rispondono adeguatamente al farmaco antipsicotico attualmente in corso |
|
|
| Not yet recruiting | 2 | 150 | Europe | Evenamide, [NW-3509], [NE-3509], Capsule, hard | NEWRON PHARMACEUTICALS SPA | Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002813-20: A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder |
|
|
| Not yet recruiting | 2 | 240 | Europe | Brexpiprazole, OPC-34712, Tablet | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Borderline Personality Disorder, Borderline Personality Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000350-26: A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study). Ensayo clÃnico para evaluar la eficacia de vafidemstat en sÃntomas negativos y deterioro cognitivo asociado a la esquizofrenia. (Estudio EVOLUTION). |
|
|
| Ongoing | 2 | 100 | Europe | Vafidemstat, ORY-2001, Capsule, hard | Oryzon Genomics, S.A., Oryzon Genomics, S.A. | Schizophrenia Esquizofrenia, Schizophrenia Esquizofrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-004752-16: A Study to Evaluate the Effects of RO6889450 (Ralmitaront) in Patients with Schizophrenia or Schizoaffective Disorder and Negative Symptoms Estudio para evaluar los efectos de RO6889450 (Ralmitaront) en pacientes con esquizofrenia o trastorno esquizoafectivo y síntomas negativos |
|
|
| Ongoing | 2 | 220 | Europe, RoW | ralmitaront, RO6889450, Capsule, hard | F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Schizophrenia or schizoaffective disorder esquizofrenia o trastorno esquizoafectivo, Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in hallucinations, delusions, and disordered behavior that impairs daily functioning Esquizofrenia: trastorno mental grave en el que las personas interpretan la realidad de forma anormal y puede resultar en alucinaciones, delirios y comportamiento desordenado que afecta el func diario, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002577-22: The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression |
|
|
| Not yet recruiting | 2 | 20 | Europe | Psilocybin 5 mg, Capsule | COMPASS Pathfinder, Limited, COMPASS Pathfinder, Limited | treatment resistant depression, treatment resistant depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000867-65: Investigation of the adhesion properties of a newly developed rotigotine-containing patch in patients with Parkinson's disease |
|
|
| Not yet recruiting | 2 | 38 | Europe | ROT-TDS 8 mg/24 h, Neupro® 8 mg/24 h, Transdermal patch, Neupro® 8 mg/24 h | Luye Pharma Switzerland AG, Luye Pharma Switzerland AG | Idiopathic Parkinson's disease, Idiopathic Parkinson's disease, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000805-26: MDMA-Assisted Psychotherapy for the Treatment of Depression |
|
|
| Not yet recruiting | 2 | 12 | Europe | 3,4-methylenedioxymethamphetamine hydrochloride/MDMA HCl /Capsule Active substance: 42542-10-9/3,4-M, Capsule | Østfold Hospital Trust, South-Eastern Norway Regional Health Authority, MAPS PBC | Major Depressive Disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000319-21: Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial)” |
|
|
| Not yet recruiting | 2 | 189 | Europe | Clonidinhydrochlorid, Doxazosinmesilat, Capsule, hard, Clonidin-ratiopharm® 75, Doxazosin STADA® 1mg Tabletten, Doxacor® 2 mg, Tabletten | Charité – Universitätsmedizin Berlin, Federal Ministry of Education and Research (BMBF) | Posttraumatic Stress Disorder Posttraumatische Belastungsstörung, Posttraumatic Stress Disorder Posttraumatische Belastungsstörung, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |